## Abstract The synthesis of a tosylate precursor for the radiosynthesis of a potential PET radiotracer, (S)‐N‐[(1‐ethyl‐2‐pyrrolidinyl)methyl]‐5‐(2‐[^18^F]fluoroethyl)‐2‐ methoxybenzamide is reported. Reaction of ^18^F‐fluoride with the tosylate provides the radiolabeled product in 10–25% yield. S
Radiosynthesis of 3-(3-[18F]fluoropropoxy)-4-(benzyloxy)-N-[(1-dimethylaminocyclopentyl)methyl]-5-methoxybenzamide, a potential PET radiotracer for the glycine transporter GlyT-2
✍ Scribed by Haibin Tian; Rebecca Vogel; Louis Amici; Gilles Tamagnan; Ronald M. Baldwin
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- French
- Weight
- 180 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The recently described selective and potent GlyT2 antagonist, 4‐benzyloxy‐3,5‐dimethoxy‐N‐[(1‐dimethylaminocyclopentyl) methyl]benzamide (IC~50~=16 nM) provided an important additional tool to further characterize GlyT2 pharmacology. In order to identify an effective PET radioligand for in vivo assessment of the GlyT‐2 transporter, 3‐(3‐[^18^F]fluoropropoxy)‐4‐(benzyloxy)‐N‐((1‐dimethylaminocyclopentyl) methyl)‐5‐methoxybenzamide ([^18^F]3), a novel analog of 4‐benzyloxy‐3,5‐dimethoxy‐N‐[(1‐dimethylaminocyclopentyl) methyl]benzamide was synthesized using a one‐pot, two‐step method. The NCA radiofluorination of 1,3‐propanediol di‐p‐tosylate in the presence of K~2~CO~3~ and Kryptofix‐222 in acetonitrile gave 81% 3‐[^18^F]fluoropropyl tosylate, which was subsequently coupled with 4‐benzyloxy‐3‐hydroxy‐5‐methoxy‐N‐[(1‐dimethylaminocyclopentyl) methyl]benzamide in the same reaction vessel. Solvent extraction and HPLC (Eclipse XDB‐C8 column, 80/20/0.1 MeOH/H~2~O/Et~3~N, 3.0 ml/min) gave [^18^F]3 in 98.5% radiochemical purity. The radiochemical yield was determined to be 14.0–16.2% at EOS, and the specific activity was 1462±342 GBq/µmol. The time of synthesis and purification was 128 min. The final product was prepared as a sterile saline solution suitable for in vivo use. Copyright © 2006 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
The glycine transporter type 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. We have recently discovered and developed [^11^C]RO5013853 as a novel positron emission tomography tracer for GlyT1 for which a reliable five‐step synthetic route was established. The incorpo